# DESCRIPTION

## FUNDING

- acknowledge funding sources

## BACKGROUND OF THE INVENTION

- describe cancer statistics
- discuss limitations of current breast cancer models

## SUMMARY OF THE INVENTION

- introduce orthotopic xenograft mouse model
- describe humanized mammary gland formation
- outline genetic modification of human stromal cells
- discuss identification of therapeutic agents
- describe assessment of breast tissue effects
- outline identification of genes contributing to breast abnormalities
- describe alteration of gene activity
- introduce immunocompromised mouse model
- describe human breast tissue in mouse model
- outline methods of generating orthotopic xenograft mouse model
- describe production of humanized mammary fat pad
- introduce method of generating humanized mammary gland
- describe modification of mice and methods
- outline methods of screening for agents modulating breast epithelial cells
- describe method of identifying drugs inhibiting abnormal growth

## BRIEF DESCRIPTIONS OF THE DRAWINGS

- describe FIGS. 1A-1F
- describe FIGS. 2A-2E
- describe FIGS. 3A-3B
- describe FIGS. 4A-4H
- describe FIGS. 5A-5F
- summarize results of GFP analysis
- describe histological analysis of xenograft breast tissue
- describe molecular analysis of xenograft breast tissue
- summarize results of hyperplastic and tumorigenic outgrowths

## DETAILED DESCRIPTION OF THE INVENTION

### I. OVERVIEW

- introduce rodent models
- describe methods of producing rodent models
- describe methods of using rodent models
- highlight utility of rodent models
- provide examples of rodents
- describe humanized mammary fat pad
- describe humanized mammary gland
- provide method of producing humanized mammary fat pad
- provide method of generating humanized mammary gland
- describe method of identifying agents affecting human breast epithelial cells
- describe method of identifying drugs inhibiting abnormal growth
- describe administration of agents or drugs
- provide additional details on humanized mammary gland

### II. DEFINITIONS

- define articles "a" and "an"
- define term "including"
- define term "or"
- define term "such as"
- define terms "polypeptide" and "protein"
- define term "recombinant"
- define term "antibody" and related terms

### III. RODENTS HAVING HUMANIZED MAMMARY FAT PADS AND METHODS OF MAKING SAME

- provide method of producing humanized mammary fat pad
- generate nontumorigenic human mammary stromal fibroblasts
- treat fibroblasts to induce proliferation and invasion
- introduce fibroblasts into cleared mammary fat pad
- allow time for fibroblasts to divide and invade
- specify embodiment with immortalized fibroblasts
- describe rodent care and maintenance
- provide embodiment with immunocompromised mice
- specify NOD/SCID mice
- describe alternative immunocompromised mice
- provide modification with non-human xenogenic mammary stromal fibroblasts
- specify primate mammary stromal fibroblasts
- describe isolation and manipulation of non-human xenogenic fibroblasts
- provide embodiment with humanized mammary fat pads
- specify #4 inguinal mammary gland modification
- describe generation of cleared mammary fat pads
- provide embodiment with two humanized mammary fat pads
- specify left and right #4 inguinal mammary glands
- describe differences between humanized mammary fat pads
- provide embodiment with immortalized nontumorigenic fibroblasts
- describe immortalization methods
- specify telomerase catalytic subunit
- describe transgene introduction methods
- provide embodiment with genetically modified fibroblasts
- specify growth factor expression
- describe polypeptide expression
- specify chemokine, cytokine, or tumor antigen expression
- provide embodiment with antibody expression
- specify breast cancer antigen antibody
- describe nucleic acid introduction methods
- provide embodiment with transgenic mice
- specify human growth factor expression
- describe physiological activation of fibroblasts

### IV. RODENTS HAVING HUMANIZED MAMMARY GLANDS AND METHODS OF MAKING SAME

- define humanized mammary gland generation method
- introduce human mammary epithelial cells into humanized mammary fat pad
- allow epithelial outgrowth development
- describe human breast duct formation
- introduce human breast epithelial stem cells as alternative
- describe humanized mammary gland formation with stem cells
- provide mouse with at least one humanized mammary gland
- describe humanized mammary gland with human breast ducts
- describe milk production in humanized mammary gland
- provide mouse with at least one functional humanized mammary gland
- describe humanized mammary gland with human breast ducts and milk production
- provide mice with two or more humanized mammary glands
- describe variations of humanized mammary fat pad
- derive human mammary epithelial cells from MEC organoids
- purchase human mammary epithelial cells from commercial sources
- isolate human mammary epithelial stem cells
- inject human mammary epithelial cells into humanized mammary fat pad
- describe composition of human mammary epithelial cells and/or human breast stem cells
- introduce human mammary epithelial cells into humanized mammary fat pad after stromal fibroblasts invasion
- coinject human breast fibroblasts with human mammary epithelial cells
- genetically modify human mammary epithelial cells, stromal fibroblasts, or breast fibroblasts
- describe tumorigenic human mammary epithelial cells
- transplant mammary fat pad from one mouse to another
- induce full differentiation and morphogenesis of epithelial outgrowth
- describe epithelial outgrowth with ductal hyperplasia, carcinoma in situ, or invasive ductal carcinoma

### V. METHODS OF USING RODENTS HAVING HUMANIZED MAMMARY GLANDS

- provide methods of using rodents having humanized mammary glands
- employ mouse variants described in the present invention
- identify an agent that affects the growth of human breast epithelial cells
- contact the agent with a humanized mammary gland of a mouse
- detect an effect of the agent on the growth of the breast epithelial cells
- select the agent which increases or decreases the growth of the breast epithelial cells
- define the term “agent”
- describe compositions, environmental factors, and methods of treatment as agents
- provide examples of agents, including chemical compounds, peptides, polypeptides, antibodies, and nucleic acid molecules
- describe RNAi constructs, including siRNAs, hairpin RNAs, and expression vectors
- explain RNA interference effects, including knockdown of a protein
- describe RNAi constructs, including short and long double-stranded RNAs
- provide examples of agents, including polypeptides and antibodies
- describe antineoplastic agents
- identify a drug that inhibits abnormal growth of human breast epithelial cells
- contact a candidate drug with a humanized mammary gland of a mouse
- determine if the candidate drug inhibits abnormal growth of the human breast epithelial cells
- select the candidate drug that inhibits abnormal growth of the human breast epithelial cells
- administer drugs or agents to mice through various routes
- determine if a drug inhibits abnormal growth, differentiation, or morphogenesis of human mammary epithelial cells
- measure the amount of programmed cell death of human mammary epithelial cells
- measure the level of angiogenesis in response to the agent or drug
- compare the number of hyperplastic growths in humanized mammary glands
- determine if a drug reduces the incidence of a particular type of hyperplasia
- determine the size of the abnormal growth or tumor
- test multiple agents for their effects on the growth, differentiation, or morphogenesis of human breast epithelial cells
- choose an appropriate control to use in the methods described herein
- provide methods of determining if a drug is specific for breast cancer
- screen candidate anti-breast cancer drugs for their effects on other assay systems
- test for the specificity of a drug for treating a given form of breast abnormality
- use mice having breast cancers reconstituted from patients having a specific form of breast cancer
- assess the effects of a candidate therapeutic in any breast abnormality
- provide variations of the methods for identifying agents and drugs
- administer the drug or agent before the mice develop functional humanized mammary glands
- study agents which affect the development of human breast from human breast stem cells

## EXEMPLIFICATION

- illustrate aspects of invention

### Experimental Procedures

- obtain human breast tissue
- isolate primary human breast fibroblasts
- infect fibroblasts with pLUC-hTERT
- infect fibroblasts with HGF or TGFβ
- generate retroviral constructs
- maintain immunocompromised NOD/SCID mice
- perform surgeries on mice
- inject human stromal cells into mice
- inject human breast epithelial organoids into mice
- prepare wholemounts for analysis
- perform immunohistochemistry
- perform genomic FISH
- perform DNA fingerprinting

## EXAMPLE 1

### Generation of “Humanized” Mammary Fat Pads

- introduce human MECs into cleared mouse mammary fat pads
- confirm failure of human MECs to colonize mouse mammary stroma
- develop line of GFP-labeled, hTERT-immortalized human mammary stromal fibroblasts
- inject fibroblasts into cleared mammary fat pads of NOD/SCID mice
- irradiate fibroblasts to facilitate engraftment and proliferation
- examine mammary fat pads for GFP expression and human fibroblast engraftment
- perform genomic FISH to confirm human fibroblast integration into mouse stroma

### EXAMPLE 2

- develop human breast ducts in chimeric mammary fat pads
- prepare human MEC organoids from reduction mammoplasty tissues
- mix organoids with primary human breast fibroblasts
- introduce mixed cell preparations into humanized mammary fat pads
- examine xenografted mammary glands for epithelial outgrowths
- observe ductal, lobular, and acinar structures
- perform genomic FISH to determine origins of epithelial and stromal cells
- examine morphology and marker expression of ductal structures
- observe active lipid synthesis and secretion in human acini
- detect human β-casein expression in luminal MECs and acini

### EXAMPLE 3

- speculate on effect of primary human mammary fibroblasts on MEC morphogenetic abilities
- introduce human mammary epithelial organoids into humanized stromal fat pads
- observe normal epithelial outgrowths with normal stromal fibroblasts
- observe abnormal human mammary epithelial structures without normal stromal fibroblasts
- conclude that normal primary fibroblasts suppress hyperplastic growths
- modify humanized stroma by forcing RMF/EG fibroblasts to express HGF or TGF-β1
- observe effects of HGF and TGF-β1 on mammary epithelial outgrowth
- introduce organoids into growth factor-enriched humanized stroma
- observe poorly developed ductal structures without normal stromal fibroblasts
- observe normal breast outgrowths with normal stromal fibroblasts
- observe ductal carcinomas without normal stromal fibroblasts
- perform immunohistological analyses to confirm transformed and invasive phenotypes
- confirm human origin of tumors by genomic FISH
- attempt to reproduce histopathological abnormalities using organoids from different region
- perform DNA fingerprinting to confirm tumor phenotype
- conclude that altered stromal environment promotes human breast cancer formation
- speculate that abnormal cells had undergone premalignant changes prior to excision

### DISCUSSION OF EXPERIMENTAL EXAMPLES

- discuss previous attempts to re-create breast tissues in mice
- explain success of irradiated fibroblasts in enabling co-introduced fibroblasts to survive
- describe activated microenvironment created by irradiated cells
- discuss importance of humanized stromal environment for engraftment of human breast epithelial cells
- explain dependence of ductal morphogenesis on admixture of primary normal breast fibroblasts
- note sufficiency of systemic hormonal environment of NOD/SCID mice for MEC proliferation
- discuss observation of hyperplasias in absence of admixed fibroblasts
- describe formation of various stages of breast cancer progression
- conclude that abnormal cells had undergone premalignant changes prior to implantation
- discuss previous reports of occult pre-neoplastic or neoplastic cells in breast tissues
- note that epigenetic alterations can be detected in morphologically normal breast tissues
- conclude that experimental system provides a unique way to study human breast cancer pathogenesis

